Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
Containsalightsolutioneasilyabsorbed,leavenon-greasyontheskin
Retatrutide sits within the broader class of incretin and metabolic peptides
Jump to: Why retatrutide isnt on the NHS yet | The realistic UK timeline | What NHS access is likely to look like | What to do in the meantime | Comparing private and NHS access | Frequently asked questions | Take home message | References You cant get retatrutide on the NHS in the UK as of 2026
PubMed Wu, X., Wang, C., Zhu, J., Zhang, C., Zhang, Y., and Gao, Y
